Get started
AMICUS THERAPEUTICS INC COM STK USD0.01AMICUS THERAPEUTICS INC COM STK USD0.01AMICUS THERAPEUTICS INC COM STK USD0.01

AMICUS THERAPEUTICS INC COM STK USD0.01

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0HF9 chart


Full chart

0HF9 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.40 B‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.4USD
Net income (FY)
‪−151.58 M‬USD
Revenue (FY)
‪399.36 M‬USD
Shares float
‪289.03 M‬
Beta (1Y)
0.60

Employees


Employees (FY)
517
Change (1Y)
+33 +6.82%
Revenue / Employee (1Y)
‪772.45 K‬USD
Net income / Employee (1Y)
‪−293.20 K‬USD

About Amicus Therapeutics, Inc.


Sector
Health Technology
CEO
Bradley Lewis Campbell
Headquarters
Princeton
Website
amicusrx.com
Founded
2002
FIGI
BBG00JVRN5G0
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas



See all ideas 

0HF9 news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0HF9 is 11.5 USD — it has decreased by −0.48% in the past 24 hours. Watch AMICUS THERAPEUTICS INC COM STK USD0.01 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange AMICUS THERAPEUTICS INC COM STK USD0.01 stocks are traded under the ticker 0HF9.
0HF9 stock has fallen by −3.10% compared to the previous week, the month change is a 8.24% rise, over the last year AMICUS THERAPEUTICS INC COM STK USD0.01 has showed a 3.32% increase.
We've gathered analysts' opinions on AMICUS THERAPEUTICS INC COM STK USD0.01 future price: according to them, 0HF9 price has a max estimate of 20.00 USD and a min estimate of 13.00 USD. Watch 0HF9 chart and read a more detailed AMICUS THERAPEUTICS INC COM STK USD0.01 stock forecast: see what analysts think of AMICUS THERAPEUTICS INC COM STK USD0.01 and suggest that you do with its stocks.
0HF9 reached its all-time high on Dec 23, 2020 with the price of 24.7 USD, and its all-time low was 6.1 USD and was reached on May 9, 2022. View more price dynamics on 0HF9 chart.
See other stocks reaching their highest and lowest prices.
0HF9 stock is 0.89% volatile and has beta coefficient of 0.60. Track AMICUS THERAPEUTICS INC COM STK USD0.01 stock price on the chart and check out the list of the most volatile stocks — is AMICUS THERAPEUTICS INC COM STK USD0.01 there?
Today AMICUS THERAPEUTICS INC COM STK USD0.01 has the market capitalization of ‪3.40 B‬, it has decreased by −1.53% over the last week.
Yes, you can track AMICUS THERAPEUTICS INC COM STK USD0.01 financials in yearly and quarterly reports right on TradingView.
AMICUS THERAPEUTICS INC COM STK USD0.01 is going to release the next earnings report on Nov 6, 2024. Keep track of upcoming events with our Earnings Calendar.
0HF9 earnings for the last quarter are −0.05 USD per share, whereas the estimation was −0.05 USD resulting in a 8.92% surprise. The estimated earnings for the next quarter are 0.00 USD per share. See more details about AMICUS THERAPEUTICS INC COM STK USD0.01 earnings.
AMICUS THERAPEUTICS INC COM STK USD0.01 revenue for the last quarter amounts to ‪126.67 M‬ USD, despite the estimated figure of ‪121.21 M‬ USD. In the next quarter, revenue is expected to reach ‪134.93 M‬ USD.
0HF9 net income for the last quarter is ‪−15.70 M‬ USD, while the quarter before that showed ‪−48.42 M‬ USD of net income which accounts for 67.58% change. Track more AMICUS THERAPEUTICS INC COM STK USD0.01 financial stats to get the full picture.
No, 0HF9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 4, 2024, the company has 517.00 employees. See our rating of the largest employees — is AMICUS THERAPEUTICS INC COM STK USD0.01 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AMICUS THERAPEUTICS INC COM STK USD0.01 EBITDA is ‪−16.68 M‬ USD, and current EBITDA margin is −16.43%. See more stats in AMICUS THERAPEUTICS INC COM STK USD0.01 financial statements.
Like other stocks, 0HF9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AMICUS THERAPEUTICS INC COM STK USD0.01 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AMICUS THERAPEUTICS INC COM STK USD0.01 technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AMICUS THERAPEUTICS INC COM STK USD0.01 stock shows the sell signal. See more of AMICUS THERAPEUTICS INC COM STK USD0.01 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.